The prostate health index (PHI) density: Are there advantages over PHI or over the prostate-specific antigen density?

Overdiagnosis of prostate cancer (PCa) should be minimized. We wanted to evaluate the diagnostic performance of the prostate health index density (PHID) and compare it with that of the prostate health index (PHI) alone and of the prostate-specific antigen density (PSAD). 232 men scheduled for a prostate biopsy (prostate-specific antigen level: 2–10 µg/L), were enrolled. PHI, PHID and PSAD were evaluated considering PCa and clinically significant...